Efficacy of phloroglucinol for the treatment of pain of gynaecologic or obstetrical origin: a systematic review of literature of randomised controlled trials

Blanchard, Clara; Paul, Vanaja; Denis, Pouchain; Mignot, Stéphanie; Vaillant-Roussel, Hélène; Boussageon, Rémy

doi:10.1007/s00228-019-02745-7

Cited by 9 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, commonly used uterine contraction inhibitors include progesterone, oxytocin antagonist, and PG antagonist (21). Phloroglucinol is a myopathic non-atropine non-papaverine smooth muscle antispasmodic with 1,3,5-trihydroxybenzene as the active ingredient (6), which has no anticholinergic effect, no effect on cardiovascular function, does not cause hypotension, has no teratogenicity, mutagenicity, or carcinogenicity, and no adverse effect on embryo and fetal development (22). In one study, researchers administered 80 mg phloroglucinol intravenously twice a day to IVF-ET-assisted pregnancy patients up to 5 days before embryo transfer, trusting that it could reduce the uterine contraction of patients and increase the clinical pregnancy rate (23).…”

Section: Discussionmentioning

confidence: 99%

“…(1) patients aged between 20 and 45 years; (2) patients with a body mass index (BMI) of 18.5-27.9 kg/m 2 ; (3) patients who met the diagnosis of endometriosis (8); (4) patients whose endometrial preparation scheme was a down-regulation scheme of gonadotropin-releasing hormone agonist (GnRH-a); (5) patients with serum cancer antigen 125 (CA 125 ) levels <35 IU/ L on the day of hormone replacement; (6) patients with an endometrial thickness ≥8 mm on progesterone conversion; (7) patients transplanted with 1 high-quality blastocyst or 1-2 cleavage stage embryos, of which at least one was a highquality embryo.…”

Section: Materials and Methods Participantsmentioning

confidence: 99%

“…Phloroglucinol is a non-atropine, non-papaverine pure smooth-muscle antispasmodic, which can reduce abnormal contraction of uterine smooth muscle, thereby helping to evade the risk of abortion (6,7). Considering that age is an independent factor affecting the success rate of embryo transfer, the effect of administering phloroglucinol to endometriosis patients at different ages, before and after frozen embryo transfer on their clinical pregnancy outcomes, was retrospectively analyzed herein to provide a clinical basis for improving the assisted pregnancy outcomes among these patients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Analysis of the effect of phloroglucinol on pregnancy outcomes involving frozen embryo transfers in patients with endometriosis: A retrospective case-control study

Pang¹,

Xing²,

Wang³

et al. 2023

Front. Surg.

View full text Add to dashboard Cite

ObjectiveAbnormal contraction of uterus and vascular smooth muscle lead to the formation of hypoxia environment in uterus. Abnormal contraction may be the basis of dysmenorrhea, endometriosis, infertility and other diseases. Phloroglucinol is a non-atropine and non-papaverine smooth muscle spasmolytic agent, which can reduce the abnormal contraction of uterine smooth muscle. This study investigated the effect of phloroglucinol on frozen embryo transfer in patients with endometriosis.MethodsThe data of patients with endometriosis who underwent a frozen embryo transfer in Shanghai Changzheng Hospital from August 2018 to August 2021, comprising a total of 453 cycles, were retrospectively analyzed. The patients for whom phloroglucinol was included over 217 cycles were administered intramuscully 40 mg phloroglucinol starting on the day of progesterone administration, then once daily up to day 7 after the embryo transfer. Those for whom phloroglucinol was not administered over 236 cycles were used as the control group. The age of 35 years was used as a boundary in this study to observe the pregnancy outcomes of patients in the two different age groups.ResultsThe biochemical pregnancy rate (63.13% vs. 51.27%), embryo implantation rate (44.64% vs. 33.60%), clinical pregnancy rate (59.64% vs. 48.30%), and live birth rate (52.99% vs. 36.86%) after the administration of phloroglucinol were higher than for patients in the control group, and the early abortion rate (7.75% vs. 20.18%) was also lower. The differences were statistically significant (P < 0.05). In particular, in the age group <35 years old, the embryo implantation rate (51.81% vs. 39.38%), clinical pregnancy rate (69.34% vs. 57.55%), and the live birth rate (63.50% vs. 44.60%) after phloroglucinol intervention rose significantly, and the abortion rate dropped (6.32% vs. 17.5%), indicating a statistically significant difference (P < 0.05). However, pregnancy outcomes showed no difference in the age group ≥35 years old (P > 0.05).ConclusionContinuous low-dose phloroglucinol pretreatment before and after frozen embryo transfer can improve both the clinical pregnancy and live birth rates and reduce the risk of abortion in younger infertile patients with endometriosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Materials and Methods Participantsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of the effect of phloroglucinol on pregnancy outcomes involving frozen embryo transfers in patients with endometriosis: A retrospective case-control study

Pang¹,

Xing²,

Wang³

et al. 2023

Front. Surg.

View full text Add to dashboard Cite

show abstract

“…Phloroglucinol, a polyphenol trihydroxybenzene with an aromatic phenyl ring and three hydroxyl groups, is a naturally occurring secondary metabolite present in a variety of organisms including plants, algae, and bacteria [ 13 , 14 ]. This phenolic compound is known to have various pharmacological potentials such as antibacterial, anticonvulsant, anti-allergic, antithrombotic, anti-inflammatory, and cancer chemopreventive activities [ 15 , 16 ]. Recently, the antioxidant potential of phloroglucinol has been validated in several in vitro and in vivo models.…”

Section: Introductionmentioning

confidence: 99%

Phloroglucinol Attenuates DNA Damage and Apoptosis Induced by Oxidative Stress in Human Retinal Pigment Epithelium ARPE-19 Cells by Blocking the Production of Mitochondrial ROS

et al. 2022

View full text Add to dashboard Cite

Phloroglucinol, a phenolic compound, is known to possess a potent antioxidant ability. However, its role in retinal cells susceptible to oxidative stress has not been well elucidated yet. Thus, the objective of this study was to evaluate whether phloroglucinol could protect against oxidative damage in cultured human retinal pigment epithelium ARPE-19 cells. For this purpose, ARPE-19 cells were stimula ted with hydrogen peroxide (H2O2) to mimic oxidative stress. Cell viability, cytotoxicity, apoptosis, reactive oxygen species (ROS) generation, mitochondrial function, DNA damage, and autophagy were then assessed. Our results revealed that phloroglucinol ameliorated cell viability, cytotoxicity, and DNA damage in H2O2-exposued ARPE-19 cells and blocked production of ROS. Phloroglucinol also counteracted H2O2-induced apoptosis by reducing Bax/Bcl-2 ratio, blocking activation of caspase-3, and inhibiting degradation of poly (ADP-ribose) polymerase. H2O2 caused mitochondrial impairment and increased expression levels of mitophagy markers such as PINK1and PARKIN known to be associated with mitochondrial ROS (mtROS) generation and cytosolic release of cytochrome c. However, these changes were significantly attenuated by phloroglucinol. Mito-TEMPO, a selective mitochondrial antioxidant, further enhanced the protective effect of phloroglucinol against dysfunctional mitochondria. Furthermore, H2O2 induced autophagy, but not when ARPE-19 cells were pretreated with phloroglucinol, meaning that autophagy by H2O2 contributed to the pro-survival mechanism and that phloroglucinol protected ARPE-19 cells from apoptosis by blocking autophagy. Taken together, these results suggest that phloroglucinol can inhibit oxidative stress-induced ARPE-19 cell damage and dysfunction by protecting DNA damage, autophagy, and subsequent apoptosis through mitigation of mtROS generation. Thus, phloroglucinol might have therapeutic potential to prevent oxidative stress-mediated damage in RPE cells.

show abstract

“…Once the ligand–receptor binding occurs, the TMPRSS2 cuts spike glycoprotein and controls the entry of viral envelopes into host cells through various synchronization changes [ 15 ]. The blockade of the ACE receptor can be controlled by inhibiting TMPRSS2 protease inhibition [ 16 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

Biochemical composition, transmission and diagnosis of SARS-CoV-2

Ahirwar¹,

Gandhi

Komal

et al. 2021

Bioscience Reports

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is a life-threatening respiratory infection caused by SARS-CoV-2, a novel human coronavirus. COVID-19 was declared a pandemic by World Health Organization in March 2020 for its continuous and rapid spread worldwide. Rapidly emerging COVID-19 epicenters and mutants of concerns have created mammoth chaos in healthcare sectors across the globe. With over 185 million infections and approximately 4 million deaths globally, COVID-19 continues its unchecked spread despite all mitigation measures. Until effective and affordable antiretroviral drugs are made available and the population at large is vaccinated, timely diagnosis of the infection and adoption of COVID-appropriate behavior remains major tool available to curtail the still escalating COVID-19 pandemic. This review provides an updated overview of various techniques of COVID-19 testing in human samples and also discusses, in brief, the biochemical composition and mode of transmission of the SARS-CoV-2. Technological advancement in various molecular, serological and immunological techniques including mainly the reverse transcription polymerase chain reaction (RT-PCR), loop-mediated isothermal amplification (LAMP), CRISPR, lateral flow assays, and immunosensors are reviewed.

show abstract

Efficacy of phloroglucinol for the treatment of pain of gynaecologic or obstetrical origin: a systematic review of literature of randomised controlled trials

Cited by 9 publications

References 23 publications

Analysis of the effect of phloroglucinol on pregnancy outcomes involving frozen embryo transfers in patients with endometriosis: A retrospective case-control study

Analysis of the effect of phloroglucinol on pregnancy outcomes involving frozen embryo transfers in patients with endometriosis: A retrospective case-control study

Phloroglucinol Attenuates DNA Damage and Apoptosis Induced by Oxidative Stress in Human Retinal Pigment Epithelium ARPE-19 Cells by Blocking the Production of Mitochondrial ROS

Biochemical composition, transmission and diagnosis of SARS-CoV-2

Contact Info

Product

Resources

About